2022
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Release

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

News

BioPharmaDive

After $250M Roche buyout, a startup plans a second strike with fresh funding

News

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

News

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

News

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

News

Endpoints

Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin

News

Also seen in

Wall Street Journal

Healthcare Investor Digitalis Ventures Nets $300 Million Fund

Article

Biopharmadive

Roche to pay $250M for Good Therapeutics and its targeted drug technology

Article

Scrip

Roche Buys IL-2 Technology From Good, Which Forms New Firm Bonum

Article

The Business Journals

Good Therapeutics being acquired by Roche for $250M

Article

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Article

MedCityNews

Roche shells out $250M to acquire Good Therapeutics and its preclinical oncology program

Article

GeekWire

Roche to acquire Good Therapeutics’ lead drug program for $250M, plus milestone payments

Article

Blog

The View from Business Development at Bonum Therapeutics

Blog

6 Drug Discovery Learnings From The Lab

Blog

Welcome to Bonum Therapeutics

Blog